Literature DB >> 23599879

Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens.

Seyed Hossein Abdollahi1, Fateme Ayoobi, Hossein Khorramdelazad, Gholamhossein Hassanshahi, Behzad Nasiri Ahmadabadi, Mohammadtaghi Rezayati, Ali Ravary, Ali Shamsizadeh, Mohammad Kazemi Arababadi.   

Abstract

OBJECTIVES: Toxoplasma gondii is a worldwide prevalent zoonotic parasite which causes toxoplasmosis. An appropriate vaccine for animals could interrupt the circle between animals and humans. Our previous study showed that excreted/secreted antigens (E/SA), derived from the peritoneum of mice infected with T. gondii tachyzoites could be considered as a good candidate for animal vaccination. Interleukin-10 (IL-10) inhibits proliferation of B and T lymphocytes and induces homeostasis in immune system responses. However, since IL-10 has also been shown to suppress the killing of T. gondii by human macrophages, the aim of this study was to evaluate IL-10 serum levels after vaccination with T. gondii E/SA prepared in vivo.
METHODS: T. gondii tachyzoites were inoculated in the peritoneum of mice and harvested E/SA were used as a vaccine, with and without adjuvant, in T. gondii infected and un-infected mice. IL-10 serum levels were evaluated using the ELISA technique.
RESULTS: The data showed that although serum levels of IL-10 were not changed at the early phases, they were elevated at the end phases of vaccination with T. gondii E/SA.
CONCLUSION: Based on these and our previous results, it can be concluded that in vivo prepared T. gondii E/SA could be considered as a good candidate for animal vaccination.

Entities:  

Keywords:  Excreted/secreted antigens; IL-10; Toxoplasma gondii; Vaccination

Year:  2013        PMID: 23599879      PMCID: PMC3628197          DOI: 10.5001/omj.2013.29

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  23 in total

1.  Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents.

Authors:  C W Angus; D Klivington-Evans; J P Dubey; J A Kovacs
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 2.  Vaccines against Toxoplasma gondii: challenges and opportunities.

Authors:  Erik Jongert; Craig W Roberts; Nicola Gargano; Elisabeth Förster-Waldl; Elisabeth Förster-Wald; Eskild Petersen
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

3.  Biological role of surface Toxoplasma gondii antigen in development of vaccine.

Authors:  Ke-Yi Liu; Dian-Bo Zhang; Qing-Kuan Wei; Jin Li; Gui-Ping Li; Jin-Zhi Yu
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  Induction of a protective antibody-dependent response against toxoplasmosis by in vitro excreted/secreted antigens from tachyzoites of Toxoplasma gondii.

Authors:  F Darcy; D Deslee; F Santoro; H Charif; C Auriault; A Decoster; V Duquesne; A Capron
Journal:  Parasite Immunol       Date:  1988-09       Impact factor: 2.280

5.  Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice.

Authors:  Mohamed El-Malky; Lu Shaohong; Takashi Kumagai; Yoshisada Yabu; Mohamed S Noureldin; Niveen Saudy; Haruhiko Maruyama; Nobuo Ohta
Journal:  Microbiol Immunol       Date:  2005       Impact factor: 1.955

6.  Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model.

Authors:  Ahmad Daryani; Ahmad Zavaran Hosseini; Abdolhossein Dalimi
Journal:  Vet Parasitol       Date:  2003-04-18       Impact factor: 2.738

7.  Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens.

Authors:  Carina Rosenberg; Stéphane De Craeye; Erik Jongert; Nicola Gargano; Elisa Beghetto; Paola Del Porto; Thomas Vorup-Jensen; Eskild Petersen
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

8.  Evaluation of excreted/secreted antigens derived from peritoneal of toxoplasma infected small mice to detect IgG against Toxoplasma.

Authors:  Seyed Ossein Abdollahi; Mohammad Kazemi Arababadi; Gholamhossein Hassanshahi
Journal:  Pak J Biol Sci       Date:  2009-03-15

9.  IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway.

Authors:  Ioannis Vouldoukis; Dominique Mazier; Daniel Moynet; Denis Thiolat; Denis Malvy; M Djavad Mossalayi
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

10.  Does Toxoplasma gondii infection affect the levels of IgE and cytokines (IL-5, IL-6, IL-10, IL-12, and TNF-alpha)?

Authors:  Joanna Matowicka-Karna; Violetta Dymicka-Piekarska; Halina Kemona
Journal:  Clin Dev Immunol       Date:  2009-05-25
View more
  7 in total

1.  Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins.

Authors:  Marcin M Grzybowski; Bożena Dziadek; Justyna M Gatkowska; Katarzyna Dzitko; Henryka Długońska
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

2.  A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models.

Authors:  Hayam Mohamed Ezz Eldin; Hanan Hussein Kamel; Abeer Fathy Badawy; Lobna Sadek Shash
Journal:  J Parasit Dis       Date:  2013-11-20

3.  Levels of Transforming Growth Factor-Beta After Immunization of Mice With in vivo prepared Toxoplasma gondii Excretory/Secretory Proteins.

Authors:  Seyed Hossein Abdollahi; Fateme Ayoobi; Hossein Khorramdelazad; Behzad Nasiri Ahmadabadi; Mohammadtaghi Rezayati; Mohammad Kazemi Arababadi; Mohammad Zare-Bidaki
Journal:  Jundishapur J Microbiol       Date:  2015-05-31       Impact factor: 0.747

4.  Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis.

Authors:  Li-Tian Yin; Hai-Xia Hao; Hai-Long Wang; Jian-Hong Zhang; Xiao-Li Meng; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

5.  Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model.

Authors:  Ying Xu; Nian-Zhang Zhang; Qi-Dong Tan; Jia Chen; Jing Lu; Qian-Ming Xu; Xing-Quan Zhu
Journal:  BMC Infect Dis       Date:  2014-09-30       Impact factor: 3.090

6.  Manipulation of IL-10 gene expression by Toxoplasma gondii and its products.

Authors:  Nader Pestechian; Hosein Khanahmad Shahreza; Roghiyeh Faridnia; Hamed Kalani
Journal:  Med J Islam Repub Iran       Date:  2016-09-06

7.  IgG subclass responses to excreted-secreted antigens of Plasmodium falciparum in a low-transmission malaria area of the Peruvian Amazon.

Authors:  Rafael Saavedra-Langer; Jorge Marapara; Andree Valle-Campos; Salomón Durand; Maria E Vásquez-Chasnamote; Hermann Silva; Viviana Pinedo-Cancino
Journal:  Malar J       Date:  2018-09-11       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.